Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO: MT-601 in Relapsed or Refractory Lymphoma
NCT05798897Phase 1Recruiting
- Sponsor
- Marker Therapeutics, Inc.
- Start
- Jan 2023
- Primary completion
- Feb 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neldaleucel in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and chronic lymphocytic leukemia (CLL), sponsored by Marker Therapeutics, Inc. Primary endpoints: Dose Escalation Safety and Tolerability at 28 days, Objective Response Rate at 12 months and 2 more. Started Jan 2023; status: recruiting.
02
Drugs
neldaleucel
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05798897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798897.